| Bioactivity | HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5)[1]. |
| Name | HDAC-IN-38 |
| CAS | 2408123-36-2 |
| Formula | C27H28ClN3O2 |
| Molar Mass | 461.98 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kaur N, et al. Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment. Eur J Med Chem. 2020 Feb 1;187:111915. |
HDAC-IN-38
CAS: 2408123-36-2 F: C27H28ClN3O2 W: 461.98
HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDA
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.